NR3C1 and Cowden syndrome 1: Mifepristone is an oral non-selective GR antagonist, officially approved in the United States in February 2012 for the treatment of CS patients who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.